---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-026689"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:11:45.930464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q2 net loss $17.4M ($0.23/sh); cash $169M; pipeline milestones on track

## Summary
- Net loss of $17.4M ($0.23 per share) vs $15.4M ($0.20) in Q2 2021; R&D expense $13.5M, G&A $4.1M.
- Cash, cash equivalents and short-term investments at $169M as of June 30, 2022.
- VK2809 Phase 2b VOYAGE study for NASH/fibrosis; enrollment completion expected in 4Q 2022.
- Phase 1 study of dual GLP-1/GIP agonist VK2735 ongoing; initial results expected by year-end 2022.
- FDA clinical hold on VK0214 Phase 1b for X-ALD lifted; dosing to resume, data expected 1H 2023.

## SEC filing metadata
- accession: 0001564590-22-026689
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/0001564590-22-026689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459022026689/vktx-8k_20220727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-026689
- JSON: https://secwatch.observer/filing/0001564590-22-026689.json
- Plain text: https://secwatch.observer/filing/0001564590-22-026689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.